<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01919216</url>
  </required_header>
  <id_info>
    <org_study_id>6038/6996R</org_study_id>
    <secondary_id>K23MH085236</secondary_id>
    <nct_id>NCT01919216</nct_id>
  </id_info>
  <brief_title>Placebo Effects in the Treatment of Depression: Cognitive and Neural Mechanisms</brief_title>
  <official_title>Placebo Effects in the Treatment of Depression: Cognitive and Neural Mechanisms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <brief_summary>
    <textblock>
      The placebo effect represents a potent treatment for MDD—placebo response in acute randomized
      controlled trials (RCTs) of antidepressant medications averages 30%, and meta-analyses have
      estimated the proportion of medication response attributable to placebo to be 50-75%. Patient
      expectancy is the mechanism of placebo effects in antidepressant RCTs and has been positively
      associated with medication response. Determining how expectancy alters the course of MDD
      could lead to methods of optimizing placebo effects and improving the treatment of MDD. In
      addition, investigating the neurobiology of placebo effects has the potential to elucidate
      the pathophysiology of MDD and the mechanisms of action of antidepressant treatments. Brain
      regions implicated in expectancy and placebo effects comprise prefrontal cortical (PFC)
      areas, amygdala, insular cortex, rostral anterior cingulate cortex (rACC), and dopaminergic
      reward pathways in the striatum. Pathological decreases in PFC and striatal function,
      increases in limbic activity, and disordered connectivity between these regions have all been
      observed in MDD, and the rostral and dorsal ACC have been repeatedly linked to antidepressant
      treatment response.

      Therefore, studying placebo effects offers a window into the functioning of the neural
      circuits that are disturbed in MDD and improve with effective treatment. The goals of this
      study are to determine whether expectancy affects the outcome of antidepressant
      pharmacotherapy and to investigate the neural mechanisms of expectancy effects. These will be
      accomplished by conducting a clinical trial randomizing adult outpatients with MDD to 8 weeks
      of treatment in high vs. low expectancy conditions. The high expectancy condition will be
      open administration of citalopram, while the low expectancy condition will be
      placebo-controlled administration of citalopram. The neural mechanisms of expectancy will be
      determined using functional Magnetic Resonance Imaging (fMRI) paradigms to investigate
      treatment activation differences in brain regions associated with placebo effects and MDD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Rating Scale for Depression</measure>
    <time_frame>8 weeks</time_frame>
    <description>The patient is rated by a clinician among 24 dimensions with a score on a 3 or 5 point scale. A score of 0-9 is considered to be normal. Score between 10-18 is considered as mild depression, Scores between 19-26 indicate moderate, scores between 27-34 indicate severe, and score between 35-75 indicate very severe depression.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Open Track</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Open treatment with 20mg of citalopram, increased to 40mg if depression has not remitted at week 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Track</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Blinded treatment with either citalopram 20mg or placebo, increased to citalopram 40mg or placebo at week 4 if depression has not remitted.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Citalopram</intervention_name>
    <arm_group_label>Open Track</arm_group_label>
    <arm_group_label>Placebo Track</arm_group_label>
    <other_name>Celexa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged 24-75 years

          -  Diagnosed with DSM IV Major Depressive Disorder, nonpsychotic

          -  24-item Hamilton Rating Scale for Depression (HRSD) score ≥ 16

          -  Willing to and capable of providing informed consent and complying with study
             procedures

          -  Subjects are right-handed

          -  Using appropriate contraceptive method if woman of child-bearing age

        Exclusion Criteria:

          -  Current comorbid Axis I DSM IV disorder other than Nicotine Dependence, Adjustment
             Disorder, Panic Disorder, Generalized Anxiety Disorder, or Social Phobia

          -  Diagnosis of substance abuse or dependence (excluding Nicotine Dependence) within the
             past 12 months

          -  History of psychosis or psychotic disorder, mania or bipolar disorder

          -  Subject is considered to be at significant risk of suicide based on current mental
             status and recent history

          -  History of allergic or adverse reaction to citalopram, or nonresponse to adequate
             trial of citalopram (at least 4 weeks at dose of 40mg) or escitalopram (at least 4
             weeks at dose of 20mg)

          -  Subject is considered based on history to be unlikely to respond to the single agent
             citalopram (i.e., subjects with treatment resistant depression)

          -  Current treatment with psychotherapy

          -  CGI-Severity score of 7 at baseline Clinical Interview

          -  Current or recent (within the past 4 weeks) treatment with any of the following:
             antidepressants, antipsychotics, mood stabilizers, isoniazid, glucocorticoids,
             opiates, centrally active antihypertensive drugs (e.g. clonidine, reserpine)

          -  Subject has metal in body or prior history working with metal fragments (e.g., as a
             machinist), tattoos, or unable to tolerate the scanning procedures (i.e., severe
             obesity, claustrophobia)

          -  Acute, severe, or unstable medical illness
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>24 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bret R Rutherford, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://sklad.cumc.columbia.edu/psychiatry/clinical_trials/View_Trial.php?ID=375&amp;type=simple</url>
    <description>Study Information</description>
  </link>
  <reference>
    <citation>Rutherford BR, Roose SP. A model of placebo response in antidepressant clinical trials. Am J Psychiatry. 2013 Jul;170(7):723-33. doi: 10.1176/appi.ajp.2012.12040474. Review.</citation>
    <PMID>23318413</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2013</study_first_submitted>
  <study_first_submitted_qc>August 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2013</study_first_posted>
  <results_first_submitted>July 24, 2017</results_first_submitted>
  <results_first_submitted_qc>December 4, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">January 5, 2018</results_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted in the Adult and Late Life Depression Research Clinic at the New York State Psychiatric Institute (NYSPI) and approved by the NYSPI Institutional Review Board. Recruitment period started January 2010 and ended in June 2016.</recruitment_details>
      <pre_assignment_details>11 enrolled participants were lost to follow up prior to randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Open Track</title>
          <description>Open treatment with 20mg of citalopram, increased to 40mg if depression has not remitted at week 4.
Citalopram</description>
        </group>
        <group group_id="P2">
          <title>Placebo Track - Citalopram</title>
          <description>Blinded treatment with either citalopram 20mg, increased to citalopram 40mg at week 4 if depression has not remitted.
Citalopram</description>
        </group>
        <group group_id="P3">
          <title>Placebo Track - Placebo</title>
          <description>Blinded treatment with either placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Open Track</title>
          <description>Open treatment with 20mg of citalopram, increased to 40mg if depression has not remitted at week 4.
Citalopram</description>
        </group>
        <group group_id="B2">
          <title>Placebo Track - Citalopram</title>
          <description>Blinded treatment with citalopram 20mg , increased to citalopram 40mg at week 4 if depression has not remitted.
Citalopram</description>
        </group>
        <group group_id="B3">
          <title>Placebo Track - Placebo</title>
          <description>Blinded treatment with placebo</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.4" spread="12"/>
                    <measurement group_id="B2" value="43.8" spread="10.7"/>
                    <measurement group_id="B3" value="34.3" spread="10.2"/>
                    <measurement group_id="B4" value="41.79" spread="11.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hamilton Rating Scale for Depression</title>
          <description>The patient is rated by a clinician among 24 dimensions with a score on a 3 or 5 point scale. A score of 0-9 is considered to be normal. Score between 10-18 is considered as mild depression, Scores between 19-26 indicate moderate, scores between 27-34 indicate severe, and score between 35-75 indicate very severe depression.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.7" spread="5.5"/>
                    <measurement group_id="B2" value="25.7" spread="4.1"/>
                    <measurement group_id="B3" value="23.8" spread="2.8"/>
                    <measurement group_id="B4" value="25.55" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hamilton Anxiety Rating Scale</title>
          <description>HAMA consists of 14 items, each defined by a series of symptoms. Each item is rated on a 5-point scale, ranging from 0 (not present) to 4 (severe). The summation of each of the 14 individually rated items will yield a comprehensive score in the range of 0 to 56. It has been predetermined that the results of the evaluation can be interpreted as follows. A score of 17 or less indicates mild anxiety severity. A score from 18 to 24 indicates mild to moderate anxiety severity. Lastly, a score of 25 to 30 indicates a moderate to severe anxiety severity.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.2" spread="4.9"/>
                    <measurement group_id="B2" value="15.1" spread="4.8"/>
                    <measurement group_id="B3" value="16.7" spread="9.2"/>
                    <measurement group_id="B4" value="14.24" spread="5.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CGI Severity</title>
          <description>Clinical Global Impression – Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment: 0 normal, not at all ill to 7 Among the most extremely ill patients</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.4" spread="0.6"/>
                    <measurement group_id="B2" value="4.3" spread="0.5"/>
                    <measurement group_id="B3" value="4.3" spread="0.6"/>
                    <measurement group_id="B4" value="4.35" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Quick Inventory of Depressive Symptoms—Self Report (QIDS-SR) 16 Item Scale</title>
          <description>The16 item Quick Inventory of Depressive Symptomatology (QIDS) contains 16 questions score from 0 to 3 each.
Qids score 1-5, not depressed; 6-10, Mild depression; 11-15, Moderate depression; 16-20, Severe depression; 21-27, very severe depression</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.7" spread="5.2"/>
                    <measurement group_id="B2" value="19.8" spread="7.2"/>
                    <measurement group_id="B3" value="17.8" spread="7.5"/>
                    <measurement group_id="B4" value="19.59" spread="6.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hamilton Rating Scale for Depression</title>
        <description>The patient is rated by a clinician among 24 dimensions with a score on a 3 or 5 point scale. A score of 0-9 is considered to be normal. Score between 10-18 is considered as mild depression, Scores between 19-26 indicate moderate, scores between 27-34 indicate severe, and score between 35-75 indicate very severe depression.</description>
        <time_frame>8 weeks</time_frame>
        <population>54 subjects participated in the study, of whom 4 (2 in open track, 1 in placebo track - citalopram, 1 in placebo track - placebo) were lost to follow-up prior to taking the study medication and were excluded from the analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Track</title>
            <description>Open treatment with 20mg of citalopram, increased to 40mg if depression has not remitted at week 4.
Citalopram</description>
          </group>
          <group group_id="O2">
            <title>Placebo Track - Citalopram</title>
            <description>Blinded treatment with either citalopram 20mg, increased to citalopram 40mg or placebo at week 4 if depression has not remitted.
Citalopram</description>
          </group>
          <group group_id="O3">
            <title>Placebo Track - Placebo</title>
            <description>Binded treatment with placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton Rating Scale for Depression</title>
          <description>The patient is rated by a clinician among 24 dimensions with a score on a 3 or 5 point scale. A score of 0-9 is considered to be normal. Score between 10-18 is considered as mild depression, Scores between 19-26 indicate moderate, scores between 27-34 indicate severe, and score between 35-75 indicate very severe depression.</description>
          <population>54 subjects participated in the study, of whom 4 (2 in open track, 1 in placebo track - citalopram, 1 in placebo track - placebo) were lost to follow-up prior to taking the study medication and were excluded from the analyses.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.79" spread="8.96"/>
                    <measurement group_id="O2" value="15.30" spread="9.2"/>
                    <measurement group_id="O3" value="12.75" spread="5.188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Open Track</title>
          <description>Open treatment with 20mg of citalopram, increased to 40mg if depression has not remitted at week 4.
Citalopram</description>
        </group>
        <group group_id="E2">
          <title>Placebo Track - Citalopram</title>
          <description>Blinded treatment with citalopram 20mg, increased to citalopram 40mg or placebo at week 4 if depression has not remitted.
Citalopram</description>
        </group>
        <group group_id="E3">
          <title>Placebo Track - Placebo</title>
          <description>Blinded treatment with placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bret Rutherford</name_or_title>
      <organization>New York State Psychiatric Institute</organization>
      <phone>6467748660</phone>
      <email>brr8@cumc.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

